The same medicinal plant can appear in more than one Indian system of medicine, and until recently each system tested it against its own pharmacopoeia. Ashwagandha or turmeric could therefore carry one set of identity, purity and assay parameters in the Indian Pharmacopoeia, which governs modern medicine, and a different set in the Ayurvedic, Siddha, Unani or Homoeopathic pharmacopoeias. For a manufacturer that meant conflicting test requirements for one raw material; for a testing laboratory it meant no single reference to work from; and for an export regulator abroad it looked like India had no settled standard at all. OHOS attacks that fragmentation at its root by developing one harmonised monograph per herb, valid across systems. A monograph is the formal reference document that fixes how a drug substance is identified, what impurities are permitted and how it is assayed. The initiative also folds in internationally used quality parameters, so that an Indian botanical monograph can stand up to scrutiny in export markets.

Three arguments carry this beyond a routine departmental renewal. First, regulatory coherence: a single reference standard removes the ambiguity that arises when two central commissions under two different ministries prescribe different parameters for the same herb, which is a textbook case of inter-ministerial harmonisation. Second, trade: the credibility of Indian botanical products in export markets rests on whether their quality claims are testable against a published, internationally aligned standard, so harmonisation is directly an ease-of-doing-business and export-promotion measure. Third, patient safety, which is the reason the standards exist at all. Herbal products are consumed on the assumption that they are what the label says, and adulteration or substitution of look-alike plant material is only detectable if the identity parameters are fixed. The three-year renewal signals that the work is being treated as a continuing programme rather than a one-off exercise, with 50 monographs already done and the next phase expected to widen the set.